Arts

The phamax ad-board services develop an advisory board, expert group or panel as per the needs of its massive stakeholder network to guide in the development phase, therapeutic area, regulatory review preparation etc. The services:

• Engage stakeholders before and after meetings for more customer touchpoints
• Envision an orchestrated, cross-country approach with expert group members from various countries
• Perform end-to-end project management with preparations, meetings and stakeholder management
• Facilitate both qualitative and focus group discussion meetings, and promote peer-to-peer stakeholder engagement
• Represent the working team as an external voice
• Handle both client and stakeholder communications

• Guidance on clinical trial protocols
• Guidance on unmet medical needs to drive future clinical strategies
• Actionable deliverables to foster positive relationships with prominent scientific community members
• Relevant and reliable educational and promotional content

Our price mapping services:

• Validate a product’s price based on its clinical profile, PLC stage, competitive landscape, and performance
• Identify a product’s optimal price range by benchmarking against suitable historical analogs
• Develop a market reference map based on the processes and regulations impacting the pricing decisions
• Build a referencing model to quantify the impact of price changes elsewhere and adapt accordingly

• Insights for the ideal product price in the market
• Unambiguous pricing decisions by assessing external events
• Maximized commercial success by optimizing a product’s geographic launch sequence

phamax HEOR services include:

• Systematic literature reviews and meta-analysis: Our systematic literature review services answer all the important questions on efficacy, safety, quality of life and resource use. We follow the PRISMA guidelines and work with clients to define the scope of project, submit the protocol, identify databases, and shortlist articles. We critically appraise relevant research and analyse data from studies to answer the clients’ research questions and also perform meta-analysis, when required
• Patient Reported Outcomes (PRO)

phamax PRO studies provide unique insights into how a therapy can affect a patient. We design studies that enable clients to capture patient perspectives on a disease/treatment under different scenarios – clinical (e.g. cure, survival), humanistic (e.g. role performance, emotional status) and economical (e.g. expenses, saving)

• Economic evaluations:

• Cost-effectiveness analysis (CEA)
• Cost-utility analysis (CUA)
• Budget-impact analysis (BIA)
• Burden of disease or Illness/Economic impact analysis

Our models estimate the costs and outcomes of interventions, and compare different interventions impacting the same health effects (usually measured as life years gained) and different health effects (usually measured as utility-based outcome units (QALYs)). HEOR models for economic evaluations are the new normal for favourable reimbursement decisions. Our services demonstrate the cost effectiveness of product vs. the competition to support reimbursement submissions and highlight the incremental effectiveness of products at multiple price points.

• Synthesis of systematically-derived data for clinical and economic analyses
• Support reimbursement decisions by evaluating the clinical and economic impact of products
• Understand the impact of technologies in a real-life context and comprehend the needs and preferences of patients
• Understand the quality of life aspects and measure the burden of the disease by incorporating all the costs associated with the disease/intervention
• Evaluate the long-term effects (length and quality of life) of an intervention on health outcomes and ease the comparison of costs and outcomes of different interventions
• Determine the impact of implementing or adopting a particular technology on a designated budget

phamax offers unparalleled commitment and quality to develop influential vantage point white papers which garner useful information about new products, markets or ways to re-hash obsolete data. We empower companies with the confidence to broadcast their products and solutions worldwide with the trustworthy information we create.

Our white paper services use:

• Extensive experience in research
• An envious panel of doctors doing primary and secondary research

• Generate leads, build mindshare and open doors to new sales opportunities
• Showcase expertise and build brand image
• Educate the audience on newer perspectives in the industry

Our KAM framework utilizes:

• Qualitative research to design the KAM working details, local KAM principles and guidelines, KAM vision, objectives, roles and responsibilities in collaboration with the client team
• Quantitative research to review the current account segmentation, KAM team workload and performance

We develop a prioritized list of recommendations and a corresponding action plan based on the qualitative and quantitative research.

• Understand the account potential, current penetration levels and value proposition
• Prioritize the list of target accounts (e.g. tier 1, 2 and 3)
• Optimal KAM team structure
• Individual account value chain
• Track account performances and relative moments (e.g. on the 3×3 grid)
• Manage the challenges effectively while implementing the KAM strategy

The phamax RWE division provides supporting evidence for a broad range of therapeutic areas. The phamax chart review services are widely applied in many healthcare-based disciplines such as epidemiology, quality assessment, professional education and residency training, inpatient care and clinical research.

Our patient chart review services use:

• Subject matter experts to deliver unique, intelligent RWE strategies to increase clinical research efficiencies
• In-house statistical teams to enhance value stories and provide compelling evidence
• Rich in-house capabilities to review and understand product and disease dynamics

• Transform complex transactional data into insights for drug utilization, prescribing trends, cost-of-care trends and health outcomes
• Determine market niches, product usage dynamics and untapped marketing opportunities
• Gain real-time insights for informed business decisions to:

• Identify gaps in care
• Stratify patient risks
• Engage stakeholders
• Create physician-patient interfaces
• Manage supply chains
• Extract hidden evidence

• Gain valuable information for direct subsequent prospective studies

The phamax patient journey offering is a proven, proprietary and solution-oriented three-pronged approach tested and validated across multiple therapy areas and companies.

A – Analyze the real-world scenarios to develop a detailed patient journey to identify hidden patient segments and barriers to access /growth drivers

E– Review the drivers and barriers with all the stakeholders to successfully expand to new segments. Prioritize the segments and develop an action plan

A – Unlock growth potential by strategically implementing the business plan at the local levels with insights from the patient journey

• Unlock growth opportunities with access to unattended patients
• Paradigm shift in marketing resource allocation and deployment
• Greater commercialization impact through targeted approaches
• Develop robust brand plans

Our local team of experts not only design but implement the strategies. The phamax range of services include:

• Market attractiveness: Assess the market size and growth, and understand the market evolution with the drivers and barriers
• Market access landscape: Identify the relevant pricing and reimbursement scenarios
• Product potential assessment: Forecast the product sales in different scenarios
• Commercial model evaluation: Develop the commercial models for own launches (in-house vs outsourced functions), out-licenses, co-promotions, co-marketing or complete divestments

• Focused and targeted strategies to optimize resources
• Realistic view of markets and product potential
• Solutions for local market access challenges
• Flexibility to choose the best-fit commercial models
• Execution speed with minimal risks

The phamax suite of forecasting services is either custom built as per your needs or comes in a ready-to-use format.

Our forecasting services use:

• Rich inhouse capabilities to review and understand disease dynamics
• Credible sources and well-documented assumptions
• Inhouse uptake curves developed over a decade with 80+ launches
• A flexible approach to adapt to the account/country/region/global levels
• Multiple statistical techniques – Regression, ARIMA, ARMA, moving averages and simulation

• Realistic view of the market and product potential
• Clearer view of the impacts of changing market environments
• Flexibility to choose the right one from multiple scenarios
• Quantify future risks
• Investment decisions to maximize product growth prospects

The phamax regulatory assessment uses three customizable dimensions:

• Research to answer key intelligence questions (KIQs)
• Collaboration with local regulatory stakeholders to address information gaps
• The phamax scientific network to refine the insights

We simplify reporting processes, making regulatory filings less demanding. We provide country-specific regulatory landscape reports using the phamax scientific network with inputs from the local regulatory systems and stakeholders. Our solutions help companies comply with the local, regional and global regulatory requirements impacting products.

The phamax regulatory services:

• Identify the regulatory requirements, and the market and customer drivers
• Develop regulatory strategies and submissions
• Help to implement compliance assurance processes
• Provide direct access to on-call consulting support
• Provide regulatory and research Q&A style support
• Provide real-time information change notices (ICNs) on important changes
• Substantiate waiver requests and read-across arguments
• Provide product safety and efficacy evaluations
• Provide third-party technical liaisons

– Understand the regulatory landscape to answer the KIQs on:

• Pricing systems
• Pricing and reimbursement processes
• Roles and responsibilities of regulatory authorities
• Recent case studies
• Health economic evidence
• Accessibility and affordability

– The realistic view of the market and product potential as per the core regulatory assessment principles
– Understand the impact of the changing market environment on the ever-changing regulatory guidelines
– Choose the right scenario from multiple options

phamax does an in-depth epidemiological analysis of therapeutic areas with primary and secondary research, real-world data and therapy-area expertise. Our scientific team includes experienced pharmaco-epidemiologists, physicians and biostatisticians. The team brings a broad range of scientific and operational experience while building forecasting models to accurately predict various epidemiological parameters such as incidence, prevalence, mortality, diagnosed population, treatment population, disease staging, risk-factors, related costs and medical management by age groups and sex. Our transparent and validated forecast models evaluating epidemiological transition and geographical extrapolation benefit global coverage.

The phamax epidemiological assessment services include:

• Burden illness analysis
• Disease prevalence and incidence analysis
• Retrospective patient chart reviews
• Longitudinal medical event database analysis
• Medical chart abstraction
• Pharma economic modeling
• Survey research (patient and physician reviews)
• Systematic literature reviews
• Targeted literature reviews
• Clinical practices
• Patient pathways
• Patient segmentation
• Assessment of unmet needs
• Disease-specific databases

• Understand the complete disease landscape and global market sizes with real-world data
• Benchmark forecasts with the total potential and addressable market data
• Identify the growth opportunities and understand how populations change over time
• Estimate the drug-treated populations with additional insights from therapeutic experts and primary market research

Our team comprises writers with advanced degrees in medicine and other branches of life sciences. We have published various scientific publications in esteemed international journals. We have a wide range of research and clinical experience in multiple therapeutic areas like cardiovascular, medical devices, endocrinology, gastroenterology, hematology, oncology, orthopedics, respiratory, rheumatology, and urology.

The phamax medical writing services include a wide range of scientific and medical documentation ranging from manuscript writing for various research studies to regulatory submissions and medical communications documents such as:

• Concept notes
• Risk management plans (RMPs)
• Clinical study reports (phase I-IV)
• Systematic reviews
• Protocols and amendments
• Investigator brochures and updates
• Manuscripts
• Abstracts, slides and poster presentations
• Medical marketing texts
• White papers
• Regulatory policy-shaping presentations

• Works independently yet collaboratively
• Produces high-quality documents with exceptional clarity, accuracy, and consistency
• Proactively maintains accurate writing and delivery timelines
• Anticipates the potential regulatory and publishing roadblocks

Our portfolio evaluation services:

• Unbiasedly assess the complete product portfolio in line with the overall company and franchise objectives
• Holistically evaluate the portfolio based on the relative attractiveness of the product, company, and market
• Clearly guide on the product-portfolio fit and optimal strategic options – invest, status quo and divest
• Deploy our extensive experience of 50+ projects with proven commercial benefits

• Higher RoI with lower portfolio costs, optimized investments, and increased profitability
• A streamlined portfolio focused on the high potential products
• Identify the opportunities from the global portfolio to strengthen the existing country portfolios
• Higher returns from the low potential and non-strategic products via collaboration with suitable external partners

phamax offers a structured approach to understand and define the market opportunities as per needs:

• The analysis of clinical factors for:

• The analysis of market factors for:

Our in-house clinical and commercial teams collect the data from reliable sources and rapidly analyze it for market insights and our investigative approach offers complete market/product assessments and capitalizes on the future opportunities for product development

• A clear understanding of the markets and their drivers
• Refined R&D strategies to focus on future market needs
• Optimized R&D investments
• Optimal resource utilization
• A set of action points to leverage opportunities

Manage your business effectively with the phamax range of business intelligence services

• Identify the KPIs for your business (Lead and Lag)
• Collect, analyze and visualize the KPIs
• Track the KPIs regularly for corrective actions

 

• Easy and quick to update data
• Real time data refresh
• On-the-go access
• Uniform view across users
• Smart data visualizations
• User-friendly navigation
• Time savings as no need to communicate with others for data collection/update

phamax offers multiple KOL services:

• Identification and profiling of KOLs/KEEs
• Identification and profiling of rising stars
• Influence mapping and network analysis of KOLs/KEEs
• Progression analysis of KOLs/KEEs
• Databases in MS Excel, MS Access and CRM applications

Our KOL services:

• Deploy In-house physician teams for qualitative insights to identify and profile KOLs
• Use different tools and advanced analytic techniques to gather data from publications, clinical trials and conferences
• Have a robust methodology to rank the KOLs/KEEs as per needs
• Do an exclusive name-matching analysis to identify unique physicians
• Map global and local KOLs/KEEs as per their involvement in activities
• Leverage flexible teams with rich experience in multiple therapeutic categories
• Track activities and update the databases regularly
• Comply to country regulations and guidelines

• Effective product strategies by engaging the right KOLs
• Brand marketing and promotional activities with the KOLs
• New product research areas
• Phase IV outcomes research
• Ready-to to-use KOLs data which to saves time and cost